疾病活动度对新生血管性年龄相关性黄斑变性患者5年治疗结局的影响
基于Fight Retinal Blindness!登记研究,纳入2109只眼,按5年内脉络膜新生血管活动就诊比例三分位分组。低、中、高活动组 adjusted 平均视力变化分别为-0.5、1.8、-2.5字母,P<0.001;低活动组更易发生黄斑萎缩,高活动组更易发生视网膜下纤维化。
要点
- 中等活动度眼5年视力结局优于高活动和低活动组。
- 低活动组黄斑萎缩发生率更高(56% vs 47% vs 26%)。
- 高活动组视网膜下纤维化发生率更高(42% vs 35% vs 27%)。
核心结论
- 高活动和低活动度眼5年结局均差于中等活动度眼,分别与视网膜下纤维化和黄斑萎缩发生相关。
研究设计与样本
- 基于Fight Retinal Blindness!前瞻性登记研究的真实世界队列,纳入2109只新生血管性年龄相关性黄斑变性眼,按5年内病变活动就诊比例三分位分组。
主要发现
- 低、中、高活动组调整后平均视力变化分别为-0.5字母(95%CI -1.8至1.1)、1.8字母(95%CI 0.2至3.4)、-2.5字母(95%CI -4.2至-1.3),P<0.001。
- 低、中、高活动组黄斑萎缩发生率分别为56%、47%、26%,P<0.001。
- 低、中、高活动组视网膜下纤维化发生率分别为27%、35%、42%,P<0.001。
临床怎么用
- 治疗新生血管性年龄相关性黄斑变性时需平衡疾病活动控制,避免过高活动导致纤维化及过低活动伴随萎缩。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the impact of disease activity on clinical outcomes in a "real-world" cohort with neovascular age-related macular degeneration over 5 years. METHODS: Data were obtained from the prospectively defined Fight Retinal Blindness! registry. Eyes were divided into tertiles based on the proportion of visits where choroidal neovascular lesion was active (low, moderate, and high) up until 5 years. RESULTS: Data from 2,109 eyes were included. The adjusted mean (95% confidence interval) visual acuity change was -0.5 letters (-1.8 to 1.1), 1.8 letters (0.2 to 3.4), and -2.5 letters (-4.2 to -1.3) in the low, moderate, and high activity groups respectively, P < 0.001. Eyes in the low activity group were more likely to develop macular atrophy (56, 47 and 26% in the low, moderate, and high activity groups respectively, P < 0.001) but less likely to develop subretinal fibrosis (27, 35 and 42% in the low, moderate, and high activity groups respectively, P < 0.001). CONCLUSION: Eyes with higher and lower levels of disease activity had poorer outcomes than eyes with moderate activity over 5 years, apparently because of the development of subretinal fibrosis or macular atrophy.
引用
- Chong Teo KY, Nguyen V, Gemmy Cheung CM, et al. THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022. PMID: 34292225. doi:10.1097/IAE.0000000000003267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。